BlackRock
AMLX icon

BlackRock’s Amylyx Pharmaceuticals AMLX Stock Holding History

BlackRock’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159M Sell
8,827,085
-1,751
-0% -$27.1K ﹤0.01% 1938
2026
Q1 		$123M Sell
8,828,836
-225,595
-2% -$3.17M ﹤0.01% 1977
2025
Q4 		$109M Buy
9,054,431
+1,913,739
+27% +$26M ﹤0.01% 2058
2025
Q3 		$97M Buy
7,140,692
+1,630,503
+30% +$15.3M ﹤0.01% 2112
2025
Q2 		$35.3M Buy
5,510,189
+3,122,780
+131% +$15.2M ﹤0.01% 2668
2025
Q1 		$8.45M Buy
2,387,409
+108,475
+5% +$386K ﹤0.01% 3400
2024
Q4 		$8.61M Sell
2,278,934
-269,272
-11% -$1.27M ﹤0.01% 3504
2024
Q3 		$8.26M Sell
2,548,206
-121,535
-5% -$273K ﹤0.01% 3500
2024
Q2 		$5.07M Sell
2,669,741
-1,804,981
-40% -$3.5M ﹤0.01% 3679
2024
Q1 		$12.7M Buy
4,474,722
+472,388
+12% +$6.18M ﹤0.01% 3227
2023
Q4 		$58.9M Buy
4,002,334
+426,875
+12% +$6.54M ﹤0.01% 2376
2023
Q3 		$65.5M Buy
3,575,459
+70,174
+2% +$1.48M ﹤0.01% 2245
2023
Q2 		$75.6M Sell
3,505,285
-109,633
-3% -$2.96M ﹤0.01% 2235
2023
Q1 		$106M Sell
3,614,918
-2,008
-0.1% -$69.8K ﹤0.01% 1980
2022
Q4 		$134M Buy
3,616,926
+1,321,092
+58% +$46.9M ﹤0.01% 1812
2022
Q3 		$64.6M Buy
2,295,834
+1,586,402
+224% +$39.6M ﹤0.01% 2263
2022
Q2 		$13.7M Buy
709,432
+137,091
+24% +$1.63M ﹤0.01% 3325
2022
Q1 		$7.35M Buy
+572,341
New +$12.9M ﹤0.01% 3749

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock's AMLX Position: Q2 2026 in Review

BlackRock reduced its Amylyx Pharmaceuticals (AMLX) stake by 0.02% in Q2 2026, selling an estimated $27.1K and leaving 8,827,085 shares worth $159M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

BlackRock first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • BlackRock held 8,827,085 shares of Amylyx Pharmaceuticals worth $159M as of Q2 2026.
  • BlackRock sold 1,751 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $27.1K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1938 holding.
  • BlackRock first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.